Kempharm Stock Performance

KMPH -  USA Stock  

USD 10.99  0.23  2.14%

On a scale of 0 to 100, Kempharm holds a performance score of 5. The company secures a Beta (Market Risk) of 0.7881, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Kempharm's beta means in this case. As returns on the market increase, Kempharm returns are expected to increase less than the market. However, during the bear market, the loss on holding Kempharm will be expected to be smaller as well. Although it is vital to follow Kempharm price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Kempharm technical indicators, you can presently evaluate if the expected return of 0.26% will be sustainable into the future. Please exercises Kempharm semi variance, and the relationship between the treynor ratio and daily balance of power to make a quick decision on whether Kempharm current price movements will revert.

Search Stock Performance 

 Kempharm Performance
5 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Kempharm are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Kempharm reported solid returns over the last few months and may actually be approaching a breakup point. ...more

Kempharm Price Channel

Quick Ratio20.58
Fifty Two Week Low4.96
Target High Price28.00
Fifty Two Week High22.08
Target Low Price10.00

Kempharm Relative Risk vs. Return Landscape

If you would invest  973.00  in Kempharm on April 30, 2021 and sell it today you would earn a total of  126.00  from holding Kempharm or generate 12.95% return on investment over 90 days. Kempharm is currently generating 0.261% in daily expected returns and assumes 3.6051% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Kempharm, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Kempharm is expected to generate 4.83 times more return on investment than the market. However, the company is 4.83 times more volatile than its market benchmark. It trades about 0.07 of its potential returns per unit of risk. The DOW is currently generating roughly 0.07 per unit of risk.

Kempharm Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Kempharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kempharm, and traders can use it to determine the average amount a Kempharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0724

Good Returns
Average Returns
Small ReturnsKMPH
Negative Returns
Estimated Market Risk
  actual daily
 30 %
of total potential
Expected Return
  actual daily
 4 %
of total potential
Risk-Adjusted Return
  actual daily
 5 %
of total potential
Based on monthly moving average Kempharm is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kempharm by adding it to a well-diversified portfolio.

About Kempharm Performance

To evaluate Kempharm Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Kempharm generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Kempharm Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Kempharm stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Kempharm's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Return on Average Assets(1.17) (1.26) 
Return on Average Equity 0.20  0.20 
Return on Invested Capital(0.41) (0.44) 
Return on Sales(0.60) (0.65) 
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company was incorporated in 2006 and is headquartered in Celebration, Florida. Kempharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.

Things to note about Kempharm

Checking the ongoing alerts about Kempharm for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kempharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Kempharm Alerts

Equity Alerts and Improvement Suggestions

Kempharm has very high historical volatility over the last 90 days
Kempharm was previously known as Kempharm and was traded on NASDAQ Exchange under the symbol KMPHD.
The company reported the previous year's revenue of 23.32 M. Net Loss for the year was (54.75 M) with profit before overhead, payroll, taxes, and interest of 11.98 M.
Kempharm currently holds about 75.92 M in cash with (2.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.66.
Kempharm has a frail financial position based on the latest SEC disclosures
Roughly 15.0% of the company outstanding shares are owned by corporate insiders
Latest headline from KMPH KemPharm Announces U.S. Launch Of Innovative ADHD Treatment Azstarys By Corium - CML News
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Bond Directory
Find actively traded corporate debentures issued by US companies
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.